Chapter 2

The Endosymbiotic Archaea, Fructose Disease and Global Warming - The Tridosha Theory of Three Humours

Endosymbiotic archaeal digoxin, hemispheric dominance and the three biological humours in Ayurveda are interrelated. The three states of biological humours described in Ayurveda have a correlation with hemispheric chemical dominance. The Kapha state represents the right hemispheric dominant hyperdigoxinemic state. The Pitta state represents the left hemispheric dominant hypodigoxinemic state. The Vata state represents the bihemispheric dominant or fluctuating dominant normodigoxinemic state. The three states of hemispheric dominance - Vata, Pitta and Kapha can differentially regulate neuro-immuno-endocrine / cellular integration. It can thus regulate the predisposition to various systemic and neuropsychiatric diseases.

Global warming induces endosymbiotic archaeal and RNA viroidal growth. The porphyrins form a template for the formation of RNA viroids, DNA viroids, prions, isoprenoids and polysaccharides. They can symbiose together to form primitive archaea. The archaea can further induce HIF alpha, aldose reductose and fructolysis resulting in further porphyrinogenesis and archaeal self replication. The primitive archaeal DNA is integrated along with RNA viroids which are converted to their corresponding DNA by the action of redox stress induced HERV reverse transcriptase into the human genome by the redox stress induced HERV integrase. The archaeal DNA sequences that are integrated into the human genome forms endogenous archaeal human genomic sequences akin to HERV sequences and can function as jumping genes regulating genomic DNA flexibility. The integrated endogenous genomic archaeal sequences can get expressed in the presence of redox stress forming endosymbiotic archaeal particles which can function as a new organelle called the archaeaons. The archaeaon can express the fructolytic pathway constituting an organelle called the fructosome, cholesterol catabolic pathway and digoxin synthetic forming an organelle called the steroidelle, the shikimic acid pathway forming an organelle called the neurotransminoid, antioxidant vitamin E and vitamin C synthetic

organelle called the vitaminocyte as well as the glycosaminoglycan synthetic organelle called glycosaminoglycoid. The archaea can secrete capsulated RNA viroidal particles which can function as blocking RNAs modulating cell metabolism and such archaeaon organelle are called viroidelle. The archaea suppresses pyruvate dehydrogenase and promotes fructolysis resulting in accumulation of pyruvate which enters the GABA shunt pathway producing succinyl CoA and glycine, the substrates for porphyrin synthesis. Porphyrin forms a template for the formation of RNA viroids, DNA viroids, prions and isoprenoids which can symbiose together to form an archaea. Thus endosymbiotic archaea have an abiogenic replication. The archaeaon concerned with GABA shunt pathway and porphyrinogenesis are called porphyrinoids. The archaeaon colony forms a network with different areas showing differential specialization of function - fructosoids, steroidelle, vitaminocyte, viroidelle, neurotransminoid, porphyrinoids and glycosaminoglycoids. This forms a living organized structure within human cells and tissues regulating their function and reducing the human body to zombie working under the directions of the organized archaeal colony. The organized archaeal colony has abiogenetic replication and is eternal.

The increase in endogenous EDLF, a potent inhibitor of membrane Na^+-K^+ ATPase, can decrease this enzyme activity. The results showed increased endogenous EDLF synthesis as evidenced by increased HMG CoA reductase activity, which functions as the rate limiting step of the isoprenoid pathway. Studies in our laboratory have demonstrated that EDLF is synthesized by the isoprenoid pathway. The endosymbiotic archaeal sequences in the human genome get expressed by redox stress and osmotic stress of global warming. This results in induction of HIF alpha which will upregulate fructolysis and glycolysis. In the setting of redox stress all glucose gets converted to fructose by the induction of enzymes aldose reductase and sorbitol dehydrogenase.

Aldose reductase converts glucose to sorbitol and sorbitol dehydrogenase converts sorbitol to fructose. Since fructose is preferentially phosphorylated by ketohexokinases the cell is depleted of ATP and glucose phosphorylation comes to a halt. Fructose becomes the dominant sugar that is metabolized by fructolysis in expressed archaeal particles in the cell functioning as organelle called fructosoids. The fructose is phosphorylated to fructose 1-phosphate which is acted upon by aldolase B which converts it into glyceraldehyde 3-phosphate and dihydroxy acetone phosphate. Glyceraldehyde 3-phosphate is converted to D 1,3-biphosphoglycerate which is then converted to 3-phosphoglycerate. The 3-phosphoglycerate is converted to 2-phosphoglycerate. 2-phosphoglycerate is converted to phosphoenol pyruvate by the enzyme enolase. Phosphoenol pyruvate is converted to pyruvate by the enzyme pyruvic kinase. The archaeaon induces HIF alpha which upregulates fructolysis and glycolysis but inhibits pyruvate dehydrogenase. The forward metabolism of pyruvate is stopped. The dephosphorylation of phosphoenol pyruvate is inhibited in the setting of pyruvic kinase inhibition. Phosphoenol pyruvate enters the shikimic acid pathway where it is converted to chorismate. The shikimic acid is synthesized by a pathway starting from glyceraldehyde 3-phosphate. Glyceraldehyde 3-phosphate combines with the pentose phosphate pathway metabolite sedoheptulose 7-phosphate which is converted to erythrose 4-phosphate. The pentose phosphate pathway is upregulated in the presence of the suppression of glycolytic pathway. Erythrose 4-phosphate combines with phosphoenol pyruvate to generate shikimic acid. Shikimic acid combines with another molecule of phosphoenol pyruvate to generate chorismate. The chorismate is converted to prephenic acid and then to parahydroxy phenyl pyruvic acid. Parahydroxy phenyl pyruvic acid is converted to tyrosine and tryptophan as well as neuroactive alkaloids. The shikimic acid pathway is structured in expressed archaeaon organelle called the neurotransminoid. The

fructolytic intermediates glyceraldehydes 3-phosphate and pyruvate are the starting points of the DXP pathway of cholesterol synthesis. Glyceraldehyde 3-phosphate combines with pyruvate to form 1-deoxy D-xylulose phosphate (DOXP) which is then converted to 2-C methyl erythritol phosphate. 2-C methyl erythritol phosphate can be synthesized from erythrose 4-phosphate a metabolite of the shikimic acid pathway. DXP combines with MEP to form isopentenyl pyrophosphate which is converted to cholesterol. Cholesterol is catabolized by archaeal cholesterol oxidases to generate digoxin. The digoxin sugars digitoxose and rhamnose are synthesized by the upregulated pentose phosphate pathway. Glycolytic suppression leads to upregulation of the pentose phosphate pathway. The expressed archaeaon organelle concerned with cholesterol catabolism and digoxin synthesis is called the steroidelle. The suppression of glycolysis and stimulation of fructolysis results in upregulation of the hexosamine pathway. Fructose is converted to fructose 6-phosphate by ketohexokinases. The fructose 6-phosphate is converted to glucosamine 6-phosphate by the action of glutamine fructose 6-phosphate amidotransferase (GFAT). Glucosamine 6-phosphate is converted to UDP N-acetyl glucosamine which is then converted to N-acetyl glucosamine and various amino sugars. UDP glucose is converted to UDP D-glucuronic acid. UDP D-glucuronic acid is converted to glucuronic acid. This forms the uronic acid synthetic pathway. Uronic acids and hexosamines form repeating units of glycosaminoglycans. In the setting of glycolytic suppression and fructolytic metabolism fructolysis leads to increase synthesis of hexosamines and GAG synthesis. The GAG synthesizing archaeaon particles are called the glycosaminoglycoids. The expressed archaeaon particles are capable of synthesizing antioxidant vitamin C and E. The UDP D-glucose is converted to UDP D-glucuronic acid. UDP D-glucuronic acid is converted to D-glucuronic acid. D-glucuronic acid is converted to L-gulonate by enzyme aldoketoreductases. L-gulonate is converted

to L-gulonolactone by lactonase. L-gulonolactone is converted to ascorbic acid by the action of archaeal L-gulo oxidase. The vitamin E is synthesized from shikimate which is converted to tyrosine and then to parahydroxy phenyl pyruvic acid. Parahydroxy phenyl pyruvic acid is converted to homogentisate. Homogentisate is converted to 2-methyl 6-phytyl benzoquinone which is converted to alpha tocopherol. 2-methyl 6-phytyl benzoquinone is converted to 2,3-methyl 6-phytyl benzoquinone and gamma tocopherol. Vitamin E can also be synthesized by the DXP pathway. Glyceraldehyde 3-phosphate and pyruvate combined to form 1-deoxy D-xylulose 5-phosphate which is converted to 3-isopentenyl pyrophosphate. 3-isopentenyl pyrophosphate and dimethyl allyl pyrophosphate combined to form 2-methyl 6-phytyl benzoquinone which is converted to tocopherols. The ubiquinone another important membrane antioxidant and part of the mitochondrial electron transport chain is synthesized by the shikimic acid pathway and DXP pathway. The isoprenoid moiety of ubiquinone is contributed from the DXP pathway and the rest of it by tyrosine catabolism. The tyrosine is generated by the shikimic acid pathway. The archaeaon particles concerned with the synthesis of vitamin C, vitamin E and ubiquinone which are all antioxidants are called the vitaminocyte.

Global warming induces endosymbiotic archaeal and RNA viroidal growth. The endosymbiotic archaea and the generated RNA viroids induce aldose reductase which converts glucose to sorbitol. The archaeal polysaccharides and lipopolysaccharides as well as viroids and viruses can induce aldose reductase. Sorbitol is acted upon by sorbitol dehydrogenase to generate fructose which enters fructolytic pathway. Aldose reductase is also induced by the osmotic stress of global warming and redox stress. Aldose reductase is induced by inflammatory and immune stimulation. Archaeal synthesized endogenous digoxin can produce intracellular redox stress and activate NFKB which produces immune activation. Both redox stress and immune activation can

activate aldose reductase which converts glucose to fructose. Hypoxic stress or anerobic conditions induces HIF alpha which activates ketohexokinase C which phosphorylates fructose. Fructose is acted upon by fructokinase which converts fructose to fructose 1-phosphate. Fructose 1-phosphate is converted to dihydroxy acetone phosphate and glyceraldehydes 3-phosphate which is converted to pyruvate, acetyl CoA and citrate. Citrate is used for lipid synthesis. Fat deposition occurs in the visceral organs like the liver, heart and kidney. There is no subcutaneous fat deposit. Fructose metabolism bypasses phosphofructokinase which is inhibited by citrate and ATP. Fructose metabolism is therefore not under the regulatory control of the enzyme phosphofructokinase. Fructose transport and metabolism is not regulated by insulin. Fructose is transported by glut-5 receptor. Fructose does not increase insulin secretion and therefore does not activate lipoprotein lipase. This results in visceral adipogenesis. Fructose induces ChREBP and SREBP elements. This results in increased hepatic lipogenesis by the induction of the enzyme fatty acid synthase, acetyl CoA carboxylase and steroyl CoA desaturace. This increases fatty acids and cholesterol synthesis. Fructose is a lipophilic carbohydrate. Fructose can be converted to glycerol 3-phosphate and fatty acids involved in triglyceride synthesis. Fructose administration leads to increase in triglycerides and VLDL. Fructose consumption leads to insulin resistance, fat accumulation in visceral organs like liver, heart and kidney, insulin resistance, dyslipidemia with increased triglycerides, VLDL and LDL as well as the metabolic syndrome. The metabolic syndrome X can be considered as a fructolytic syndrome. Fructose will increase lipid storage and promote insulin resistance. Fructose can fructosylate proteins producing dysfunction. Fructose has no effect upon ghrelin and leptin in the brain and can lead to increased feeding behaviour. Glucose decreases ghrelin and increases leptin levels. This leads to suppression of appetite. Thus fructose can modulate eating behaviour leading onto obesity.

Fructose results in NFKB activation and TNF alpha secretion. TNF alpha can modulate the insulin receptor producing insulin resistance and metabolic syndrome X. Fructose can also lead to leptin resistance and obesity. There is an epidemic of metabolic syndrome X in relation to global warming.

Fructose can activate the sympathetic nervous system. This leads to hypertension and increase in heart rate. Fructose is involved in left ventricular hypertrophy, increase in left ventricular mass and decrease in left ventricular ejection fraction in hypertension. Fructose suppresses the parasympathetic nervous system. Fructose acts as a key inducer for uncontrolled proliferation and hypertrophy of the cardiac musculature consequent to hypertension. The heart uses beta oxidation of fatty acids to generate energy. In the setting of anerobic glycolysis consequent to myocardial infarction and hypertensive hypertrophy of the heart, there is induction of HIF alpha. This produces increase in ketohexokinase C in the heart which phosphorylates fructose. Ketohexokinase C is a predominant liver enzyme as fructose metabolism is primarily focused in the liver. In the setting of anerobic glycolysis ketohexokinase C is also produced in the brain and the heart. Ketohexokinase A is the predominant enzyme in the heart and brain. In the setting of anerobic glycolysis ketohexokinase A which preferentially metabolizes glucose is converted to ketohexokinase C metabolizing fructose by the mechanism of RNA splicing. Anerobic conditions can induce HIF alpha which activates the splicing factor SF3B1. Thus HIF alpha induced by glycolysis induces SF3B1 which induces ketohexokinase C producing fructolysis in the heart. The fructose is converted to lipids, glycogen and glycosaminoglycans in the heart producing cardiac hypertrophy. Fructose metabolism is not under regulatory control of the key enzyme phosphofructokinase by citrate and ATP. The fructolytic pathway functions as a rogue pathway not under any regulatory control. Fructose is a key contributor. The sympathetic overactivity and parasympathetic blockade consequent to fructose can produce immune activation.

The sympathetic overactivity and parasympathetic blockade can lead to dysregulation of the nervous system.

Fructose can activate NFKB and tumour necrosis factor alpha. The vagal blockade produced by fructose also leads to increase in immune activation. Fructose can inhibit neutrophilic phagocytosis. Increased fructose ingestion can lead to immune activation and respiratory diseases like chronic bronchitis, COPD and bronchial asthma as well as interstitial lung disease. This immune activation induced by fructose is called as fructositis. Fructosylated proteins can serve as autoantigens. Fructosylated proteins can bind to RAGE receptors producing immune activation. Global warming induced fructose disease is the basis of the epidemic of autoimmune disease rising with the global warming.

Fructose increases flux through the pentose phosphate pathway. This increases the availability of hexose sugars like ribose for nucleic acid synthesis. This increases DNA synthesis. There is also consequent increase in protein synthesis. The tumour cells can slurp up fructose. Tumour cells utilise fructose for proliferation. The fetal cells like tumour cells also utilize fructose for proliferation. Fructose can promote metastatic deposits. The tumour cells use fructose differently from glucose. Cancer cells utilize fructose to support proliferation and metastasis. Fructose increases nucleic acid synthesis. Fructose can help the cancer cells to grow fast by inducing the transketolase enzyme and the pentose phosphate pathway. Fructose administration increases redox stress, DNA damage and cell inflammation all contributing to oncogenesis. Fructose is the most abundant sugar in the fetal tissues and is important in the development of fetus by promoting cell proliferation. Fructose is 20-times more concentrated in the fetal blood than glucose. Sperm cells and ova also use fructose for metabolism and energy. Thus all rapidly proliferating cells - cancer cells, fetal cells and reproductive cells depends upon fructolysis. Fructose is the principal diet of the cancer cells. Global warming and archaeal growth results in HIF

alpha induction. HIF alpha induces tumour growth. HIF alpha also increases glycolysis. But archaeal induced HIF alpha also induces aldose reductase which converts glucose to fructose and metabolism proceeds along the fructolytic pathway. Fructosylation of glycolytic enzymes brings glycolysis to a halt. Fructosylation of mitochondrial PT pore hexokinase can result in PT pore dysfunction and cell proliferation. The fructolytic pathway is the principal energetic pathway for rapidly proliferating cancer cells, fetal cells and stem cells. The global warming will induce the Warburg phenotype of the fructolytic variety. This leads to an epidemic of cancer. There is an epidemic of cancer in relation to global warming. The fructolytic pathway can lead to increased DNA synthesis and RNA synthesis due to flux via the pentose phosphate pathway. The fructolytic pathway can be directed to the GABA shunt generating succinyl CoA and glycine. These are substrates for porphyrin templates to form RNA viroids. The archaeal induced redox stress can induce endogenous HERV expression and reverse transcriptase expression. The RNA viroids are converted by HERV reverse transcriptase to corresponding DNA and integrated into the genome by HERV integrase. The integrated RNA viroid related DNA can function as jumping genes producing genomic plasticity and genomic change.

Fructose as said before induces the thiamine dependent transketolase flux. It increases both the oxidative and non oxidative pentose phosphate pathway. This increases nucleic acids and glycosaminoglycan synthesis. Fructose is converted to fructose 1-phosphate which is acted upon by aldolase B converting it into glyceraldehyde and dihydroxy acetone phosphate. Glyceraldehyde is converted glyceraldehyde 3-phosphate by triokinase. DHAP can be converted to glyceraldehyde 3-phosphate by the enzyme triose phosphate isomerase. Glyceraldehyde 3-phosphate can be converted to pyruvate. This pyruvate can be channeled to gluconeogenesis and glycogen storage by the action of the enzyme pyruvate carboxylase. This results in the conversion of glyceraldehyde

3-phosphate to pyruvate and via pyruvate carboxylase to glucose 1-phosphate. Glucose 1-phosphate is converted to glycogen polymers. Thus fructolysis results in glycogen storage. The pyruvate that is generated by fructolysis is converted to glutamate which can enter the GABA shunt pathway. The GABA shunt pathway generates glycine and succinyl CoA which are substrates for ALA synthesis. Thus fructolysis stimulates porphyrin synthesis. The porphyrins can self organize to form supramolecular arrays called porphyrions. Porphyrions can self replicate by using other porphyrions as templates. Porphyrions can have energetic and ATP synthesis by electron or photon transport. Porphyrions are dipolar molecules and in the setting of digoxin induced membrane sodium potassium ATPase inhibition can generate a pumped phonon system induced quantal state and quantal perception. They can function as quantal computers with information storage. The porphyrions are basic self replicating living structures. The porphyrins can act as a template for the formation RNA, DNA and proteins. The RNA viroids, the DNA viroids and proteins generated by abiogenesis on porphyrin templates can self organize to form primitive archaea. The archaea are thus capable of abiogenic replication on porphyrin templates. The archaea can induce HIF alpha and further aldose reductase induction promoting fructolysis.

Fructose is an addictive substance. Fructose affects the hedonic centres in the brain concerned with pleasure and reward. In the addiction scale fructose is more addictive then cocaine and cannabis. Fructose decreases BDNF. Low BDNF produces changes in the brain resulting in schizophrenia and depression. Fructose can also produce chronic inflammation involved in schizophrenia. The fructolytic pathway is important in the genesis of psychiatric disorders. The increased fructolysis can lead to fructosylation of lipoproteins especially apoprotein E and apoprotein B. Apo B can undergo lysine fructosylation leading to defective LDL and cholesterol uptake by the brain. This results in

autism and schizophrenia. Fructolysis leads to cholesterol depletion of the brain. Cholesterol is required for the formation of synaptic connections and cerebral cortex. This leads to cerebral cortical atrophy and cerebellar dominance in the presence of cholesterol depletion. This can contribute to the genesis of the cerebellar cognitive affective syndrome, the basis of schizophrenia and autism. There is an epidemic of schizophrenia and autism correlating with global warming. Fructosylation of LDL and brain cholesterol depletion can lead to dysfunction in synaptic transport. There is more release of glutamate into the synaptic from the presynaptic neuron consequent to a presynaptic neuron membrane dysfunction as a result of cholesterol depletion. This contributes to glutamate excitotoxicity. Glutame excitotoxicity can contribute to neuronal degeneration. Fructose can also produce zinc deficiency. Increased fructose intake produces zinc depletion leading to defective formation of metallothionines leading to defective heavy metal excretion. This leads to mercury, cadmium and aluminium toxicity in the brain leading to psychiatric disorders like autism and degenerations like Alzheimer's disease. Zinc deficiency consequent to fructose excess can lead to copper excess. The zinc containing neurons in the cerebral cortex are called the gluzinergic neurons. The cerebral cortex especially the prefrontal cortex will atrophy producing cerebellar and brain stem dominance. Copper is required for the dominance of subcortical cognitive structures. Fructose ingestion can also lead to calcium deficiency which can produce defective calcium signaling. Fructose ingestion leads to fructolysis and the generation of reactive species 3-deoxyglucosone important in mallard reachion and fructosylation of neuronal proteins leading to their defective function. Neuropsychiatric disorders and neurodegenerative disorders can be described as fructose diseases. Topiramate a fructose analogue is used to treat motor neuron disease. Fructose biphosphate aldolase B mutation has been seen in schizophrenia, bipolar disorders and depression.

6-phosphofructo 2-kinase and fructose 2,6-biphosphotase abnormalities have been seen in schizophrenia. Fructose metabolism abnormalities have been noted in schizophrenia, manic depressive psychosis and autism. Fructose inhibits brain plasticity. Fructose inhibits the ability of neurons to communicate with each other. The wiring and re-wiring of neurons is inhibited. Fructose leads to a neuronal disconnection syndrome.

Fructose can increase flux via the pentose phosphate pathway and hexosamine pathway leading to glycosaminoglycan synthesis. Glycosaminoglycan accumulation in the tissues can produce mucopolysaccharidosis and fibrosis. Increased heparan sulphate accumulation in the brain leads to formation of amyloids plaques and Alzheimer's disease. Connective tissue accumulation in the lung leads to interstitial lung disease in the kidneys it produces tubular atrophy and a chronic renal failure similar to meso-American nephropathy. Connective tissue accumulation in the heart can lead to a restrictive cardiomyopathy. Accumulation of GAG especially hyaluronic acid in bones and joints leads to osteoarthritis and spondylosis. GAG accumulation in the endocrine organs can produce thyroid dysfunction resulting in MNG and thyroiditis, pancreatic dysfunction producing chronic calcific pancreatitis and adrenal dysfunction producing hypoadrenalism. Accumulation of GAG in the vascular tissues can result in mucoid angiopathy contributing to coronary artery disease and stroke. The accumulation of lipids due to the fructolytic pathway along with glycosaminoglycans can lead to fatty liver. This can later lead onto cirrhosis of the liver. Fructose is the principal culprit for fatty liver and cirrhosis. The glycine synthesized from the fructolytic intermediate phosphoglycerate can play a role inhibiting fatty liver. There is an epidemic of chronic renal failure due to tubular fibrosis, mucoid angiopathic vascular diseases, cardiomyopathy, multiple endocrine failures, cirrhosis of the liver, interstitial lung disease, degenerative

bone and joint diseases and degenerative brain disease like Alzheimer's disease and Parkinson's disease as a consequence of global warming.

The increasing growth of archaea results in increased secretion of archaeal RNA viroids. They can interrupt mRNA function and dysregulates cell metabolism. This is by the mechanism of mRNA blockade. The viroidal RNA can combine with proteins generating prion proteins. This produces a protein conformation defect. This produces a prion protein disease. Abnormal protein conformation of beta amyloid, alpha synuclein, ribonucleoproteins, islet associated amyloid polypeptide and tumour suppressor protein can lead to an epidemic of Alzheimer's disease due to beta amyloid accumulation, alpha synuclein accumulation producing Parkinson's disease, prion like ribonucleoproteins producing motor neuron disease, metabolic syndrome X due to defective insulin secretion as a result of IAPP and abnormal prion like tumour suppressor protein producing tumours. These prion diseases induced by archaeal RNA viroids are also transmissible. Thus global warming related fructolysis leads to archaeal induced RNA viroidal mediated prion disease and amyloidosis. This raises the spectacle of a Cassandra syndrome of human extinction.

Fructose is phosphorylated to fructose 1-phosphate by ketohexokinase C or fructokinase. Fructose 1-phosphate is converted to glyceraldehyde which is then converted to glyceraldehyde 3-phosphate and dihydroxy acetone phosphate (DHAP). Fructose 1-phosphate is cleaved to DHAP and glyceraldehyde 3-phosphate. DHAP can enter the glycolytic pathway or can go to gluconeogenetic pathway. DHAP generated from fructose 1-phosphate by the action of aldolase B is acted upon by triose phosphate isomerase converting it into glyceraldehydes 3-phosphate. Glyceraldehyde 3-phosphate can be fructolysed to pyruvate and acetyl CoA. Acetyl CoA can be used for cholesterol synthesis for storage. The pyruvate generated from glyceraldehydes 3-phosphate can be converted to the citrate which can be used for fatty acid

synthesis by the action of enzymes acetyl CoA carboxylase, fatty acid synthase and malonate dehydrogenase. Glyceraldehyde is acted upon by alcohol dehydrogenase which converts it into glycerol. Glycerol is acted upon by glycerolkinase converting it into glycerol phosphate used for phosphoglyceride and triglyceride synthesis. Glyceraldehyde can also be acted upon by triokinase converting it into glyceraldehydes 3-phosphate which is then converted to DHAP by triose phosphate isomerase. Glyceral phosphate and dihydroxy acetone phosphate are interconvertible by the action of the enzyme glycerol phosphate dehydrogenase. Glycerol and fatty acids generated by fructolysis contribute to lipid synthesis and fat is stored. Fructose does not increase insulin secretion and doesn't need insulin for transport into the cell. Fructose is transported by the fructose transporter GLUT-5. Ketohexokinase C is exclusively seen in the liver which is the principal site of fructose metabolism. In the presence of hypoxia and anerobic states, there is induction of HIF alpha which can induce ketohexokinase C or fructokinase in the liver, kidney, gastrointestinal tract, brain and heart. Fructose 1-phosphate by-passes the enzyme phosphofructokinase which is the key regulatory enzyme the glycolytic pathway. Phosphofructokinase is inhibited by ATP and citrate. Thus stress induced fructolysis is an unregulated pathway not amenable to metabolic switches. Fructose does not depend upon insulin for its transport and fructolysis. Therefore fructolysis is not under insulin or endocrine control. It is an unregulated pathway.

The phosphorylation of fructose depletes the cell of ATP. Ketohexokinases preferentially phosphorylate fructose over glucose if it is available. In the presence of redox stress, osmotic stress and archaea/viroids aldose reductase is induced converting all the glucose to fructose. Glycolytic pathway comes to a halt as no ATP is available for phosphorylation of glucose and glucose as such gets converted to fructose. The fructose phosphorylation depletes the cell of

ATP. ATP is converted to ADP and AMP which is deaminated to produce uric acid. Fructose increases flux in the pentose phosphate pathway increasing nucleic acid synthesis. Purine degradation results in hyperuricemia. Thus fructolysis results in increase in uric acid accumulation in the body. Uric acid will suppress the mitochondrial oxidative phosphorylation as well as produce endothelial dysfunction. The depletion of ATP by fructose phosphorylation results in membrane sodium potassium ATPase inhibition. This results in reduced energy needs of the cell as 80% of the ATP generated by metabolism is used for maintaining the sodium potassium pump. This results in membrane ATPase inhibition generated hibernatory state. The glyceraldehydes 3-phosphate generated by fructolysis can be converted to the pyruvate and acetyl CoA used for cholesterol synthesis. The cholesterol that is synthesized is used for digoxin synthesis. Digoxin also has got aglycone part which contains sugars like digitoxose and rhamnose. Digitoxose and rhamnose are generated by the fructose induced flux and upgradation of the pentose phosphate pathway. Thus fructolysis results in a hyperdigoxinemic state and membrane sodium potassium ATPase inhibition. This results in cell protection and hibernation.

Fructose produces flux along the pentose phosphate pathway and hexosamine pathway. This results in GAG and nucleic acid synthesis. Fructose is converted to fructose 1-phosphate which is then converted to ribulose 5-phosphate. Ribulose 5-phosphate is acted upon by an isomerase converting it into xylulose 5-phosphate and ribose 5-phosphate. Xylulose 5-phosphate and ribose 5-phosphate interact to produce glyceraldehydes 3-phosphate and sedoheptulose 7-phosphate which is then converted to fructose 6-phosphate and erythrose 4-phosphate. The pentose phosphate pathway generates ribose for nucleic acid synthesis. The pathway also generates hexosamines for GAG synthesis. The pentose phosphate pathway also produces digitoxose and rhamnose for digoxin synthesis.

The global warming results in endosymbiotic archaeal growth. Archaea can induce aldose reductase which converts glucose to fructose. Fructolysis promotes flux along the pentose phosphate pathway generating nucleic acids and glycosaminoglycans. Fructolysis also generates glyceraldehydes 3-phosphate and further pyruvate. The pyruvate can enter the pyruvate carboxylase scheme generating gluconeogenesis and glycogen synthesis. Thus fructolysis can produce glycogen storage. Pyruvate can be converted to citrate for lipid synthesis. Pyruvate can also be converted to acetyl CoA for cholesterol synthesis. The flux along the pentose phosphate pathway generates the digoxin sugars, digitoxose and rhamnose. Cholesterol can be converted to digoxin producing a hyperdigoxinemic state. Digoxin produces membrane sodium potassium ATPase inhibition. The selective phosphorylation of fructose by fructokinase depletes the cell of ATP producing membrane sodium potassium ATPase inhibition. This results in the generation of a hibernatory state. The fructolysis generated pyruvate can get converted to glutamate which can enter the GABA shunt pathway producing succinyl CoA and glycine for porphyrin synthesis. Porphyrins can form self replicating porphyrions or act as a template for the formation of RNA viroids, DNA viroids and prions which can symbiose to form archaea. Thus the archaea are capable of self replicating on porphyrin templates. The fructolysis thus produces a hibernatory syndrome with fat, glycogen and nucleic acid synthesis and storage. Fructolysis results in the generation of a hibernatory species, the homo neanderthalis. The fructolysis generated membrane sodium potassium ATPase inhibition results in cell hibernation and ATP sparing. The lack of ATP and digoxin induced membrane sodium potassium ATPase inhibition results in cortical inhibition and cerebellar dominance. This produces a somnolent state and a cerebellar cognitive affective disorder. The porphyrions generated by fructolysis produces quantal perception and cerebellar dominance. The storage of glycogen, fat and GAG results in

obesity. The cerebellar cognitive affective syndrome results in a hypersexual state. The fructolysis and fructose can activate NFKB producing immune activation. The fructosylation of glycolytic and mitochondrial proteins suppresses the body's normal energetic which depends upon glycolysis and mitochondrial oxidative phosphorylation. Fructosylation of proteins results in blockade of glycolysis and mitochondrial oxidative phosphorylation. The body's energy needs are produced by fructolysis, porphyrin array mediated electron transport chain and ATP synthesis as well as membrane sodium potassium ATPase inhibition relation ATP synthesis. This produces a new species by archaeal symbiosis consequent to global warming - the homo neanderthalis. This can be called as the tropical hibernatory syndrome consequent to global warming.

This can be called also as a fructose disease. Endosymbiotic archaea and viroids induce aldose reductase and converts body glucose to fructose leading to preferential fructose phosphorylation by ketohexokinase C. Fructolysis results in fructose 1-phosphate being acted upon by aldolase B resulting in the formation of glyceraldehyde and dihydroxy acetone phosphate. Glyceraldehyde can be converted to glyceraldehyde 3-phosphate and this contributes to pyruvate formation. Pyruvate enters the GABA shunt resulting in the formation of succinyl CoA and glycine. They are substrates for porphyrin synthesis and porphyrion formation. The porphyrins form a template for the formation of RNA viroids, DNA viroids, prions, isoprenoids and polysaccharides. They can symbiose together to form primitive archaea. The archaea can further induce HIF alpha, aldose reductose and fructolysis resulting in further porphyrinogenesis and archaeal self replication. The archaea by methanogenesis contributes to global warming which leads to further archaeal growth and a vicious cycle with no regulatory switches. The fructolytic pathway induced by archaea by-passes regulatory enzyme phosphofructokinase and is practically

unregulated. Fructolytic pathway contributes to glycogen, lipids, cholesterol, hexose sugars and mucopolysaccharides synthesis and storage. This leads onto a hibernatory state and archaeal symbiosis induced species change resulting in neanderthalisation of the homo sapien species. The digoxin and fructose phosphorylation induced ATP depletion leads to membrane sodium potassium ATPase inhibition, sparing of ATP and tissue hibernation as most of the energy needs of the body are for the working of the sodium potassium pump. The cholesterol that is synthesized by fructolysis is catabolized cholesterol oxidases for archaeal energetics. Archaea also derives its energy from a primitive form of electron transport chain functioning in self replicating porphyrin arrays. The archaeal digoxin induced sodium potassium ATPase inhibition can lead to membrane ATP synthesis. The archaea and the new human species phenotype derives its energy from the above mentioned mechanism. The glycolytic enzymes and the mitochondrial PT pore hexokinase are fructosylated making them dysfunction. The fructosylated glycolytic enzymes lead to generation of antiglycolytic enzyme antibodies and disease states. The human body's principal method of energetics tissue glycolysis and oxidative phosphorylation comes to a grinding halt. The human body is taken over by the overgrowth of endosymbiotic archaea and assumes hibernatory state with accumulation of glycogen, lipids, mucopolysaccharides and nucleic acids. The catabolic pathways for energy generation related to glucose, glycolysis and oxphos scheme stops. The human body can depend upon ketogenesis from fat and proteins. The upregulated fructolytic pathway generates phosphoglycerate which converted to phosphoserine and glycine. They can be converted to other amino acids and used for ketogenesis. The body assumes a high BMI index and obesity with visceral fat storage and adiposity akin to the Neanderthal metabolic phenotype. Digoxin induced membrane sodium potassium ATPase inhibition results in cortical dysfunction. The brain porphyrins can form a quantal pumped

phonon system resulting in quantal perception and low level EMF absorption. This leads to prefrontal cortex atrophy and cerebellar dominance. Fructose itself leads to sympathetic hyperactivity and parasympathetic blockade. This leads onto a functional form of cerebellar cognition and quantal perception resulting in a new brain phenotype. The cerebellar cognitive syndrome leads to a robotic human phenotype. The phenotype is impulsive, has extrasensory perception and has less of speech production. Communication is by symbolic acts. The cerebellar phenotype doesn't have a cortical control and contributes to surrealistic behavior patterns. This produces impulsive behavior and an epidemic of surrealism where the rational prefrontal cortex becomes extinct. This leads to extremes of spirituality, violent and terroristic behavior and hypersexual states contributing to a state of trancedence underlined and reinforced by quantal perception. Cerebellar phenotype owing to its quantal perception behaves as a community and not as an individual. This creates new social and psychological phenotypes. Fructose induces NFKB and immune activation. This results in an immune activatory phenotype. Cultured T-reg cells on high fructose diet have 62% less IL-40 secretion than controls. This results in a hyperimmune state with fructosylated proteins acting as antigens. The fructolytic pathway can lead to increased DNA synthesis and RNA synthesis due to flux via the pentose phosphate pathway. The fructolytic pathway can be directed to the GABA shunt generating succinyl CoA and glycine. These are substrates for porphyrin templates to form RNA viroids. The archaeal induced redox stress can induce endogenous HERV expression and reverse transcriptase expression. The RNA viroids are converted by HERV reverse transcriptase to corresponding DNA and integrated into the genome by HERV integrase. The integrated RNA viroid related DNA can function as jumping genes producing genomic plasticity and genomic change. This produces a new genotype. Fructosylation of body proteins and enzymes results in a protein processing

defect resulting in loss of protein function. The human cell function due to protein fructosylation, protein processing defects and protein conformational defects comes to a grinding halt. Fructolytic pathway generates porphyrin arrays induced ATP production, membrane sodium potassium ATPase inhibition induced ATP synthesis and fructolysis induced ATP generation. This provides energy for porphyrin template induced archaeal replication. The digoxin and fructose phosphorylation induced ATP depletion produces cell membrane sodium potassium ATPase inhibition and a hibernatory state. This leads onto a somnolent sleepy state. The cholesterol catabolism by cholesterol oxidases for archaeal energetics leads to defective sex hormone synthesis. This leads onto an asexual androgynous state. The cerebellar cognitive syndrome due to prefrontal cortical atrophy consequent to porphyrion induced low level EMF perception produces a hypersexual state. This results in male-female equidominance and changes in sexual behavior of the population. Thus the fructose disease consequent to global warming results in a new neuronal, immune, metabolic, sexual and social phenotype. The human body is converted to a zombie for the global warming related endosymbiotic archaea to thrive. The neuronal, metabolic, sexual and social phenotype creates the necessary environment endosymbiotic archaeal multiplication and the human body is converted to a zombie phenotype. This can be called as a hibernatory zombie syndrome. Due to the new sexual and social phenotype with asexuality and hypersexuality and female-male equidominance the human population falls. The global warming and archaeal induction of HIF alpha resulting in the Warburg phenotype leads to changes in the metabolic scheme of the cells producing body cell transformation to stem cells. The stem cells depend upon glycolysis or fructolysis for energy needs. The Warburg phenotype produces an acidic pH which can result in conversion of body cells to stem cells. The stem cells conversion results in loss of tissue function. The cerebral cortex synaptic connectivity is lost and becomes

dysfunction leading to subcortical cerebellar dominance. The immune stem cells proliferate producing an autoimmune disease. The various tissue cells the specialized function like neuron, nephron and muscle cell all because of stem cell conversion becomes dysfunctional. This produces a stem cell syndrome with human somatic cells being converted to stem cells with loss of function and uncontrolled proliferation. The fructosylation of proteins results in protein function defects. The fructosylation of LDL results in defective cholesterol transport to the cells. This results in steroidal hormone synthesis defects. Cholesterol is required for formation of synaptic connectivity and this leads to cerebral cortical dysfunction. The hemoglobin becomes fructosylated and oxygen transport is affected. This leads to hypoxia and anerobic states. The hypoxia and anerobic states induces HIF alpha and the Warburg fructolytic phenotype. The HIF alpha also induces aldose reductase converting glucose to fructose and inducing the fructolytic scheme. The fructolysis induced GABA shunt pathway and porphyrin synthesis results in further archaeal porphyrin template related replication. This results in further archaeal induced fructolysis and the vicious irreversible cycle proceeds. The uncontrolled growth of archaea leads to still further global warming. The world of endosymbiotic eternal archaea takes over and persists during the extremophilic climatic changes of global warming. The human beings exist as neanderthalic zombies serving archaeal multiplication. The homo sapiens gets converted to a new phenotype, genotype, immunotype, metabolonomic type and brain type. This is called as hibernatory zombie related to global warming - homo neoneanderthalis.

Table 1

	Serum fructose		**Serum fructokinase**		**Aldolase B**		**Total GAG**	
	Mean	**± SD**	**Mean**	**± SD**	**Mean**	**± SD**	**Mean**	**± SD**
Normal	2.50	0.195	8.5	0.405	3.50	1.304	3.50	0.707
Sy X	21.20	5.201	18.91	2.942	8.01	1.244	18.46	4.623
CAD	31.40	3.212	21.18	2.267	9.02	0.667	21.41	1.653
CVA	29.98	4.002	24.96	3.829	11.72	1.397	21.65	2.755
DCM/EMF	32.04	4.955	21.37	2.050	10.89	1.344	20.12	2.855
Tumour	27.94	3.732	22.29	1.237	9.46	1.386	20.89	1.651
Schizo	31.14	4.446	22.19	2.634	11.63	3.081	21.50	1.714
Autism	28.66	5.089	24.09	2.146	12.30	1.621	22.60	3.054
AD	33.13	2.754	19.87	1.646	11.37	1.406	22.97	3.662
PD	30.24	4.551	22.72	1.955	11.93	2.999	20.13	1.507
MS	29.88	5.150	22.29	1.641	10.87	1.895	23.47	2.878
Lupus	33.11	4.509	20.24	1.639	11.59	0.767	20.62	3.504
CRF	30.24	3.209	22.52	3.196	11.76	1.596	20.55	2.164
ILD	32.04	5.295	22.37	1.585	11.84	0.963	21.49	1.544
COPD	26.68	4.266	21.78	2.253	10.62	1.703	22.84	2.965
BA	33.59	3.938	22.45	2.472	11.30	0.783	23.50	3.225
Cirrhosis	32.53	6.737	23.00	1.722	10.49	1.373	20.57	1.878
IBD	31.75	5.236	21.89	2.292	11.63	1.304	22.46	4.030
MAO	31.53	4.507	22.07	2.324	11.32	1.343	23.89	2.936
IBS	29.90	4.299	22.52	1.995	10.93	1.498	22.09	2.797
PUD	32.49	6.487	21.89	3.431	10.85	1.606	25.27	3.693
EMF	30.79	4.740	21.47	3.056	11.65	1.427	20.54	2.192
CCP	31.16	3.635	22.42	3.126	10.49	1.476	17.94	2.276
MNG	32.24	5.864	20.46	2.864	9.82	1.135	21.42	2.662
Muc ANG	30.40	6.405	23.30	4.089	11.08	1.360	22.16	3.543
DBJD	33.06	5.970	22.42	3.714	11.21	1.660	17.76	3.556
Spondylosis	32.70	4.430	21.92	1.840	14.10	2.423	26.80	3.679
F value	17.373		13.973		13.903		21.081	
p value	< 0.01		< 0.01		< 0.01		< 0.01	

Table 2

	Total TG		**Serum ATP levels**		**Uric acid**		**Anti-aldolase**	
	Mean	**± SD**	**Mean**	**± SD**	**Mean**	**± SD**	**Mean**	**± SD**
Normal	124.00	3.688	2.50	0.405	5.70	0.369	7.50	1.704
Sy X	262.40	32.790	0.82	0.143	6.21	0.452	2.20	0.583
CAD	252.44	35.388	0.85	0.085	9.00	0.485	2.23	0.567
CVA	297.64	36.410	0.79	0.081	9.34	1.641	2.02	0.303
DCM/EMF	302.00	25.166	0.77	0.151	9.26	1.048	1.41	0.310
Tumour	277.60	34.613	0.80	0.136	7.88	0.847	1.45	0.415
Schizo	244.00	31.383	0.72	0.102	8.65	0.701	1.35	0.319
Autism	284.30	19.743	0.87	0.072	8.14	0.538	1.35	0.218
AD	244.70	22.106	0.82	0.121	8.74	0.687	1.70	0.361
PD	284.30	19.945	0.83	0.090	8.90	0.579	2.03	0.232
MS	289.89	23.406	0.74	0.115	9.59	0.783	1.80	0.402
Lupus	294.00	39.903	0.78	0.161	8.34	0.712	1.81	0.691
CRF	272.10	31.057	0.86	0.101	7.76	0.798	1.67	0.363
ILD	292.10	26.337	0.78	0.135	8.40	0.442	1.72	0.360
COPD	306.40	24.419	0.74	0.136	9.62	0.952	1.63	0.440
BA	293.80	31.555	0.72	0.134	9.51	1.059	2.10	0.572
Cirrhosis	271.80	37.818	0.79	0.150	8.12	0.747	1.67	0.377
IBD	287.50	20.414	0.77	0.102	9.44	0.924	1.30	0.223
MAO	316.20	31.283	0.76	0.103	9.32	0.864	1.41	0.307
IBS	279.10	27.606	0.77	0.095	9.68	1.060	1.44	0.350
PUD	285.70	22.628	0.76	0.126	9.77	0.957	1.14	0.134
EMF	270.10	28.792	0.81	0.079	8.76	0.881	1.31	0.329
CCP	293.00	28.111	0.78	0.145	8.30	0.966	1.31	0.265
MNG	262.70	30.324	0.83	0.091	8.04	0.667	1.55	0.493
Muc ANG	275.40	30.351	0.77	0.138	8.83	0.633	1.47	0.466
DBJD	282.60	27.573	0.79	0.136	8.28	0.978	1.89	0.315
Spondylosis	295.30	16.600	0.72	0.108	10.21	1.310	1.54	0.377
F value	16.378		59.169		14.166		55.173	
p value	< 0.01		< 0.01		< 0.01		< 0.01	

Table 3

	Anti-enolase		**Anti-pyruvatekinase**		**Anti-GAPDH**	
	Mean	**± SD**	**Mean**	**± SD**	**Mean**	**± SD**
Normal	1.50	0.358	50.40	5.960	5.20	0.363
Sy X	0.51	0.185	17.04	3.556	1.73	0.371
CAD	0.55	0.154	16.06	6.811	1.78	0.349
CVA	0.66	0.182	21.79	4.567	1.50	0.307
DCM/EMF	0.49	0.197	18.68	4.585	1.54	0.471
Tumour	0.42	0.182	19.93	2.421	1.39	0.253
Schizo	0.40	0.142	22.02	11.954	1.31	0.235
Autism	0.20	0.060	19.27	2.201	1.20	0.205
AD	0.38	0.205	18.87	3.899	1.37	0.305
PD	0.42	0.208	20.11	3.220	1.44	0.342
MS	0.39	0.124	18.93	6.447	1.78	0.355
Lupus	0.42	0.116	18.59	3.721	1.48	0.258
CRF	0.55	0.220	17.06	3.449	1.32	0.358
ILD	0.52	0.202	18.80	3.221	1.41	0.355
COPD	0.59	0.159	18.14	3.500	1.71	0.509
BA	0.36	0.177	15.33	3.212	1.72	0.277
Cirrhosis	0.48	0.273	18.60	2.915	1.52	0.287
IBD	0.43	0.163	17.06	4.366	1.40	0.298
MAO	0.44	0.230	19.08	3.396	1.48	0.220
IBS	0.57	0.242	19.99	2.637	1.39	0.289
PUD	0.51	0.221	20.63	5.116	1.42	0.329
EMF	0.42	0.182	14.55	3.133	1.24	0.239
CCP	0.50	0.149	17.82	2.889	1.44	0.234
MNG	0.47	0.151	17.59	2.469	1.44	0.270
Muc ANG	0.36	0.114	18.63	3.147	1.48	0.271
DBJD	0.54	0.211	22.48	4.638	1.33	0.302
Spondylosis	0.40	0.134	19.91	5.099	1.49	0.282
F value	14.091		21.073		58.769	
p value	< 0.01		< 0.01		< 0.01	